Miravitlles Marc, Huerta Alicia, Fernández-Villar José Alberto, Alcázar Bernardino, Villa Guillermo, Forné Carles, Cuesta Maribel, Crespo Carlos, García-Río Francisco
Health Qual Life Outcomes. 2014 Sep 5;12:120. doi: 10.1186/s12955-014-0120-5.
To determine generic utilities for Spanish chronic obstructive pulmonary disease (COPD) patients stratified by different classifications: GOLD 2007, GOLD 2013, GesEPOC 2012 and BODEx index.
Multicentre, observational, cross-sectional study. Patients were aged ≥40 years, with spirometrically confirmed COPD. Utility values were derived from EQ-5D-3 L. Means, standard deviations (SD), medians and interquartile ranges (IQR) were computed based on the different classifications. Differences in median utilities between groups were assessed by non-parametric tests.
346 patients were included, of which 85.5% were male with a mean age of 67.9 (SD = 9.7) years and a mean duration of COPD of 7.6 (SD = 5.8) years; 80.3% were ex-smokers and the mean smoking history was 54.2 (SD = 33.2) pack-years. Median utilities (IQR) by GOLD 2007 were 0.87 (0.22) for moderate; 0.80 (0.26) for severe and 0.67 (0.42) for very-severe patients (p < 0.001 for all comparisons). Median utilities by GOLD 2013 were group A: 1.0 (0.09); group B: 0.87 (0.13); group C: 1.0 (0.16); group D: 0.74 (0.29); comparisons were statistically significant (p < 0.001) except A vs C. Median utilities by GesEPOC phenotypes were 0.84 (0.33) for non exacerbator; 0.80 (0.26) for COPD-asthma overlap; 0.71 (0.62) for exacerbator with emphysema; 0.72 (0.57) for exacerbator with chronic bronchitis (p < 0.001). Comparisons between patients with or without exacerbations and between patients with COPD-asthma overlap and exacerbator with chronic bronchitis were statistically-significant (p < 0.001). Median utilities by BODEx index were: group 0-2: 0.89 (0.20); group 3-4: 0.80 (0.27); group 5-6: 0.67 (0.29); group 7-9: 0.41 (0.31). All comparisons were significant (p < 0.001) except between groups 3-4 and 5-6.
Irrespective of the classification used utilities were associated to disease severity. Some clinical phenotypes were associated with worse utilities, probably related to a higher frequency of exacerbations. GOLD 2007 guidelines and BODEx index better discriminated patients with a worse health status than GOLD 2013 guidelines, while GOLD 2013 guidelines were better able to identify a smaller group of patients with the best health.
确定按不同分类分层的西班牙慢性阻塞性肺疾病(COPD)患者的一般效用值,这些分类包括:《慢性阻塞性肺疾病全球倡议》(GOLD)2007版、GOLD 2013版、西班牙慢性阻塞性肺疾病流行病学研究组(GesEPOC)2012版和巴塞罗那慢性阻塞性肺疾病指数(BODEx指数)。
多中心、观察性横断面研究。患者年龄≥40岁,经肺功能检查确诊为COPD。效用值来自欧洲五维度健康量表(EQ - 5D - 3L)。根据不同分类计算均值、标准差(SD)、中位数和四分位间距(IQR)。通过非参数检验评估组间中位数效用值的差异。
纳入346例患者,其中85.5%为男性,平均年龄67.9(SD = 9.7)岁,COPD平均病程7.6(SD = 5.8)年;80.3%为既往吸烟者,平均吸烟史为54.2(SD = 33.2)包年。根据GOLD 2007版,中度患者的中位数效用值(IQR)为0.87(0.22);重度患者为0.80(0.26);极重度患者为0.67(0.42)(所有比较p < 0.001)。根据GOLD 2013版,A组的中位数效用值为:1.0(0.09);B组为0.87(0.13);C组为1.0(0.16);D组为0.74(0.29);除A组与C组外,比较均有统计学意义(p < 0.001)。根据GesEPOC表型,非急性加重期患者的中位数效用值为0.84(0.33);慢性阻塞性肺疾病 - 哮喘重叠综合征患者为0.80(0.26);合并肺气肿的急性加重期患者为0.71(0.62);合并慢性支气管炎的急性加重期患者为0.72(0.57)(p < 0.001)。有或无急性加重期患者之间以及慢性阻塞性肺疾病 - 哮喘重叠综合征患者与合并慢性支气管炎的急性加重期患者之间的比较有统计学意义(p < 0.001)。根据BODEx指数,0 - 2组的中位数效用值为:0.89(0.20);3 - 4组为0.80(0.27);5 - 6组为0.67(0.29);7 - 9组为0.41(0.31)。除3 - 4组与5 - 6组之间外,所有比较均有统计学意义(p < 0.001)。
无论采用何种分类,效用值均与疾病严重程度相关。一些临床表型与较差的效用值相关,可能与更高的急性加重频率有关。与GOLD 2013版指南相比,GOLD 2007版指南和BODEx指数能更好地区分健康状况较差的患者,而GOLD 2013版指南更能识别出健康状况最佳的较小患者群体。